COURSE DIRECTOR

Giovanni Di Perri

Head of the Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Italy

COURSE SCIENTIFIC SECRETARIAT

Stefano Bonora

Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Italy

Phone + 39 011 4393980/4393867, Fax +39 011 4393882
E-mail stefano.bonora@unito.it

Andrea Calcagno

Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Italy

Phone + 39 011 4393980/4393867, Fax +39 011 4393882
E-mail andrea.calcagno@unito.it

DATES AND SCHEDULE

WEDNESDAY 19 JAN 2022

2:40 PM - 6:45 PM

THURSDAY 20 JAN 2022

9:00 AM - 6:30 PM

FRIDAY 21 JAN 2022

9:00 AM - 1:30 PM

COURSE RATIONALE

The COVID-19 pandemic has placed infection research into the spotlight, highlighting once again the complexity and devastating impact that infectious diseases can have.
Continuous advances in disease management require the ongoing attention of healthcare professionals. This course will bring together research experts from different fields to present current knowledge, strategies and approaches on viral infections (HIV, HBV, HCV, HDV, SARS-CoV2), but also to put this knowledge into the context of other infectious diseases (bacterial). The implications of new PK/PD information on strategies for clinical management of patients with infections will be addressed in depth.
Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert panel of clinicians and researchers. The three-day course will bring together researchers and clinicians from various parts of the world to discuss pro and cons of current PK/PD strategies in anti-infective area. Each topic focus on preclinical, translational and clinical aspects and will provide opportunity for discussion and input from the audience. This meeting will be a valuable experience for all involved in infectious diseases, as researchers or prescribers of anti-infective agents.


LEARNING OBJECTIVES

Participants will be taught on learning goals:

  • Recognize the role of PK/PD parameters for the management of HIV, HBV and HCV infections.
  • Focus on recent developments regarding PK variability of antivirals and its association with specific tissue drug penetration and clearance.
  • Describe the challenges of HIV, HBV and HCV treatment as it relates to cure and selection of drug resistance.
  • Discuss treatment options for COVID-19, focusing on drug strategies and patient immune system response.
  • Develop strategies to modify viral treatment regimens based on individual patient response.
  • Devise a plan to manage drug interactions and adverse effects anti-infective treatments and optimize treatment responses.
  • Present real and typical clinical scenarios, discuss findings and management in the light of current PK/PD data and clinical practices guidelines.